Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024, reflecting a significant reduction in costs [17] - Revenues for 2025 totaled approximately $3.9 million, down from approximately $5.6 million in the previous year, primarily due to lower revenue from AgPlenus [22] - The net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the same period last year, indicating improved financial performance [31] Business Line Data and Key Metrics Changes - R&D expenses for 2025 were approximately $8 million, a decrease of approximately $4.5 million compared to 2024, mainly due to reduced expenses in Biomica, Casterra, and AgPlenus [24] - Sales and marketing expenses for 2025 were approximately $1.5 million, down from approximately $2 million in the previous year, reflecting cost-cutting measures [25] - AgPlenus continues to apply ChemPass AI for the development of novel herbicides and fungicides, with expectations for growth through collaborations with Bayer and Corteva [14] Market Data and Key Metrics Changes - Casterra Ag ceased operations in Kenya and is focusing on the Brazilian market, leading to an impairment of approximately $2.2 million related to seed inventory [19] - The agricultural market has seen a decline in demand, affecting Casterra's operations, but there is an expectation of increased collaboration opportunities as the need for innovation grows [41] Company Strategy and Development Direction - The company has shifted its focus to two high-impact markets: human health and agriculture, utilizing the ChemPass AI platform for drug development and ag chemicals [8] - The strategic transformation includes discontinuing non-core activities and resizing the organization to enhance operational efficiency [7] - The long-term goal is to develop a proprietary product pipeline while becoming the partner of choice for small molecule discovery and optimization [15] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of strategic partnerships and collaborations to enhance the company's capabilities and market position [12] - The company expects to maintain sufficient cash flow for operations for at least a year and a half, even without additional financial transactions [36] - Management anticipates significant future catalysts, including technology collaborations and partnerships with larger biotech and ag chemical companies [39][41] Other Important Information - The company recognized a gain on the sale of Lavie Bio's assets, amounting to approximately $6.4 million, which contributed to the income from discontinued operations [31] - As of December 31, 2025, the company held approximately $13 million in cash equivalents and short-term bank deposits [21] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on the advancement of BMC128 and revenue sharing from the end product [34] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year, with sufficient cash for over a year and a half [36] Question: What are the expected investor catalysts over the coming 12 months? - Anticipated catalysts include technology collaborations with companies like Google, additional agreements with biotech and pharma companies, and collaborations with ag chemical companies [39][41]

Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024, reflecting a significant reduction in costs [17] - Total operating expenses net for Q4 2025 were approximately $3.2 million, down from approximately $4.3 million in Q4 2024 [17] - Revenues for 2025 totaled approximately $3.9 million, a decrease from approximately $5.6 million in the previous year, primarily due to lower revenue from AgPlenus [22] - Net loss for 2025 was approximately $7.8 million, a decrease from approximately $18.1 million in the previous year, attributed to reduced operating expenses and income from discontinued operations [31] Business Line Data and Key Metrics Changes - AgPlenus, the agriculture subsidiary, continues to apply ChemPass AI for developing novel herbicides and fungicides, with expectations for growth through collaborations with Bayer and Corteva [14] - Casterra Ag ceased operations in Kenya and recorded an impairment of approximately $2.2 million related to seed inventory due to a decline in demand for castor seeds [19][23] - Biomica scaled down operations and entered into a license agreement with Lishan Pharmaceuticals for its lead oncology candidate, BMC128 [18] Market Data and Key Metrics Changes - The agriculture industry has faced negative performance in recent years, impacting collaboration appetites, but there is a growing need for innovation [41] - The company anticipates that cash from Lavie Bio and Biomica will satisfy operational needs for at least the next year and a half [36] Company Strategy and Development Direction - The company has focused its technology development on a single computational engine, ChemPass AI, and streamlined operations to concentrate on human health and agriculture [8] - The mission is to design novel small molecules optimized for drug development and agricultural chemicals, leveraging ChemPass AI's capabilities [7][15] - The company aims to become the partner of choice for small molecule discovery and optimization in both pharma and agriculture sectors [15] Management Comments on Operating Environment and Future Outlook - Management highlighted the strategic transformation to direct resources for sustainable value creation, emphasizing the competitive advantage of ChemPass AI [6][8] - The company expects to scale collaborations and partnerships, enhancing the likelihood of advancing proprietary candidate molecules [12][14] - Management expressed confidence in achieving targets and continuing to update stakeholders on progress [43] Other Important Information - The company recognized a gain on the sale of Lavie Bio's assets, contributing to income from discontinued operations [31] - Cash position as of December 31, 2025, was approximately $13 million, with cash usage during Q4 2025 at approximately $3 million [21][22] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on advancing BMC128 in the pipeline and revenue sharing from the end product [34] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year, with sufficient cash for over a year and a half [36] Question: What are the expected investor catalysts over the coming 12 months? - Three types of catalysts are anticipated: technology collaborations with companies like Google, additional collaborations with biotech and pharma companies, and collaborations with ag chemical companies [37][41]

Financial Data and Key Metrics Changes - Operating expenses net for 2025 decreased to approximately $13.8 million from approximately $22 million in 2024 [16] - Total operating expenses net for Q4 2025 were approximately $3.2 million, down from approximately $4.3 million in Q4 2024 [16] - Revenues for 2025 totaled approximately $3.9 million, a decrease from approximately $5.6 million in 2024 [21] - Net loss for 2025 was approximately $7.8 million compared to approximately $18.1 million in the previous year [30] - Operating loss for Q4 2025 was approximately $5.2 million, an increase from approximately $3.5 million in Q4 2024 [26] Business Line Data and Key Metrics Changes - Lavie Bio Ltd. completed the sale of the majority of its operations, significantly reducing its operational expenses [17] - Biomica scaled down operations and entered into a license agreement with Lishan Pharmaceuticals for its lead oncology candidate [17] - AgPlenus integrated into core operations, focusing on novel ag chemical products [18] - Casterra Ag ceased operations in Kenya and recorded an impairment of approximately $2.2 million related to its seed inventory [18][22] Market Data and Key Metrics Changes - The demand for castor seeds significantly declined, impacting Casterra's operations [18] - The agriculture industry has faced negative performance, affecting collaboration willingness, but there are signs of improvement [40] Company Strategy and Development Direction - The company has focused on two high-impact markets: human health and agriculture, utilizing ChemPass AI for drug development and ag chemicals [8] - A strategic transformation was initiated to streamline operations and enhance long-term value creation [6] - The mission is to become the partner of choice for small molecule discovery and optimization in pharma and agriculture [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of reduced expense levels and the potential for cash inflow from Lavie Bio and Biomica [35] - The company anticipates significant future collaborations with technology and pharmaceutical companies, which could serve as catalysts for growth [36][40] Other Important Information - The company held consolidated cash equivalents of approximately $13 million as of December 31, 2025 [20] - Financing income net for 2025 was approximately $0.6 million, a decrease from approximately $4 million in the previous year [26] Q&A Session Summary Question: Can you speak to the terms of the BMC128 license agreement with Lishan Pharmaceuticals? - The agreement includes milestone payments based on advancing BMC128 and revenue sharing from the end product [33] Question: Can you speak to the magnitude of cash potentially coming in from Lavie Bio and Biomica? - Expected cash from Lavie Bio and Biomica will satisfy operational needs for at least mid-next year [35] Question: What are the expected investor catalysts over the coming 12 months? - Three types of catalysts were identified: technology collaborations, additional pharma collaborations, and ag chemical collaborations [36][40]